JRF GLOBAL

RECENT JRF STUDIES RECEIVE APPROVAL AT US EPA

July 31, 2015

As part of a recent regulatory submission (June 2015) a number of JRF studies were reviewed and classified as '**Acceptable: - Guideline**' by US EPA.

The registration submission included a number of complicated studies from JRF's preclinical EDSP Tier-I, Immunotox, Neurotox and DART divisions. The regulatory submission timelines required a strong combination of scientific excellence and project management skills to deliver study data within tight time and quality expectations.

This adds further experience with US EPA regulatory submissions to JRF's preclinical portfolio building on a number of previous US EPA submissions over the past three years.

"*We are delighted with the approval and acceptance of our client's study data*" said **Dr. Abhay Deshpande, Director Global - JRF**. "*We are proud to offer our scientific contributions to preclinical services globally. We strongly believe these positive achievements position us as a global CRO with strong and reliable scientific, quality and project management capabilities for our global clients*"

About JRF Global

JRF Global is a multinational Contract Research Organization, with an expansive portfolio of non-clinical regulatory research services. We serve our global client base by offering high quality GLP studies and ensuring rapid turnaround time, on-time delivery and constant communication and updates.

For Further information, please contact your local representative or JRF Global at
bd@jrfonline.com.
Visit our website: ***www.jrfglobal.com***